Renal Failure News and Research

RSS

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Hope in sight for sufferers of chronic renal disease

Miss M. spends around 15 hours a week in hospital. Her renal functions are limited, and her kidneys are no longer able to filter toxins from her blood. She is a dialysis patient, forced to rely on this artificial blood purification treatment that, although essential, greatly impairs her quality of life. She has to make three trips a week to the dialysis clinic and going away for longer than a few days is almost out of the question. And Miss M. is no exception: In Germany alone, over six million people suffer from some form of chronic renal disease.

17 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Blood conservation strategy during AVR can reduce costs, complications

Incorporating a blood conservation strategy (BCS) during aortic valve replacement (AVR) can reduce the likelihood of transfusion-related complications, as well as reduce blood-product utilization, according to a study in the January 2014 issue of The Annals of Thoracic Surgery.

2 Jan 2014

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

27 Dec 2013

Most frequent reasons for readmission often related to patients' underlying chronic medical conditions

Researchers cite identification and monitoring of known underlying chronic medical conditions as opportunities to reduce readmission rates and improve patient safety.

24 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD).

12 Dec 2013

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Researchers from the Cardiovascular Institute at Rhode Island, The Miriam and Newport hospitals will present 22 abstracts, both poster and oral presentations, at the upcoming American Heart Association Scientific Sessions, to be held in Dallas November 16-20, 2013. Scientific Sessions is the foremost cardiovascular research meeting in the U.S., with more than 18,000 cardiovascular experts from more than 105 countries in attendance.

16 Nov 2013

Thomas Jefferson University's Department of Medicine named Comprehensive Hypertension Center

The Department of Medicine at Thomas Jefferson University has been named a Comprehensive Hypertension Center by the American Society of Hypertension (ASH). Jefferson is one of only five in the country to earn top recognition for its advanced diagnosis, evaluation and treatment of complex hypertension and associated disorders.

4 Nov 2013

Enterocystoplasty: A good surgical option for children with genitourinary abnormalities

Enterocystoplasty is a good surgical option with a low rate of severe complications in the treatment of children who were born with developmental abnormalities of the genitourinary system, according to the new study conducted by a group of Portuguese urologists.

30 Oct 2013

Renal Failure News and Research

Further Reading

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Hope in sight for sufferers of chronic renal disease

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Blood conservation strategy during AVR can reduce costs, complications

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Most frequent reasons for readmission often related to patients' underlying chronic medical conditions

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Emergent BioSolutions enters into definitive agreement to acquire Cangene

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

Detectable blood viral load increases prevalence of heart disease

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Thomas Jefferson University's Department of Medicine named Comprehensive Hypertension Center

Enterocystoplasty: A good surgical option for children with genitourinary abnormalities

Free guide - Everything about renal proximal tubule cells eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News